GlassScriptPhysician profile
Krista Feind
NPI 1508518853
$1,131.14
in general payments reported to CMS, 2019-2025
23 companies · $162 in 2025
The $162 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $576 · 2024: $394 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,131.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $214.84 | 2024-2025 | Opdivo, Opdualag |
| Glaxosmithkline, LLC. | $93.16 | 2023-2024 | Zejula, Jemperli |
| Immunogen, INC. | $91.09 | 2023 | Elahere |
| Janssen Biotech, INC. | $73.40 | 2023 | Stelara |
| Astellas Pharma US INC | $72.50 | 2024-2025 | Veozah |
| Ardelyx, INC. | $63.29 | 2023 | Ibsrela |
| Merck Sharp & Dohme LLC | $55.69 | 2024 | Keytruda |
| Ipsen Biopharmaceuticals, INC | $54.33 | 2024 | Somatuline Depot, Onivyde |
| Genzyme Corporation | $50.95 | 2023 | |
| Abbvie INC. | $47.89 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.50 | 2023 | Xifaxan, Plenvu |
| Ferring Pharmaceuticals INC. | $36.07 | 2023 | Rebyota |
| Celltrion USA INC. | $31.97 | 2023 | Vegzelma |
| Daiichi Sankyo INC. | $29.37 | 2024 | Injectafer |
| Medtronic, INC. | $24.97 | 2025 | Truclear |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $21.97 | 2024 | Cabometyx |
| Lilly USA, LLC | $21.27 | 2024 | Jaypirca, Retevmo, Verzenio |
| Qol Medical, LLC | $21.25 | 2023 | Sucraid |
| Stemline Therapeutics INC. | $21.19 | 2024 | Orserdu |
| Pfizer INC. | $20.01 | 2024 | |
| Braintree Laboratories, INC. | $17.22 | 2023 | Sutab |
| Takeda Pharmaceuticals U.S.A., INC. | $17.03 | 2023 | Entyvio |
| Intercept Pharmaceuticals, INC. | $13.18 | 2023 | Ocaliva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krista Feind listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.